omniture
信达生物

Latest News

Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX

SUZHOU, China, June 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2020-06-22 07:40 2454

Innovent Announces the NMPA Granted Marketing Approval for BYVASDA® (Bevacizumab Biosimilar) in China

SUZHOU, China, June 19, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a w...

2020-06-19 12:20 8171

Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China

SUZHOU, China, June 18, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a...

2020-06-18 12:00 2649

Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

SUZHOU, China, June 9, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-06-09 07:30 2618

Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

SUZHOU, China, June 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-06-09 07:30 969

Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study

SUZHOU, China, June 3, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a wo...

2020-06-03 07:30 4486

Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study

SUZHOU, China, June 2, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a wo...

2020-06-02 07:30 3843

Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)

SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-06-01 07:30 1040

Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)

SUZHOU, China, June 1, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-06-01 07:30 3032

Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China

SUZHOU, China, May 26, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a ...

2020-05-26 07:30 6998

Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers

SUZHOU, China, and HOUSTON, May 19, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKE...

2020-05-19 07:30 3761

Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

SUZHOU, China, May 15, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") ...

2020-05-15 07:30 5002

Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China

SUZHOU, China, April 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company...

2020-04-28 07:50 7306
1234